In This Section      
 

Search Results

Title:
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)
Protocol Number:
ETCTN10129
Phase:
Phase II
Physician:
Nilofer Azad
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
To estimate the overall response rates of olaparib in subjects with recurrent/progressive IDH1/2-mutant solid tumors, who will be recruited to 3 cohorts: glioma, cholangiocarcinoma, other solid malignant tumors.
Eligibility:
Age 18 years or older. ECOG 0-2. Adequate organ and bone marrow function. Life expectancy at least 16 weeks. No previous treatment with olaparib or any other PARP inhibitor. Tumor must be easily accessible for biopsy.
Treatment:
Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Imaging will be completed every 8 weeks.
Population:
Adult
Last Update
03/05/2019 05:03 AM